● BLSM shares jumped 14.91% without a defining company announcement, reflecting a broader lift in risk appetite across biotech.
● GENB shares climbed 15.01% amid a broad re-rating of AI-enabled and computational drug-discovery names, without a single company-specific catalyst.
● MRNA shares rose 14% as investors continued to reward the Phase 3 success of Moderna and Merck's individualized cancerVaccinein melanoma.
● TENX shares jumped 25.41% in a rebound that recovers only a fraction of the value erased when the stock plunged roughly 90% on August 10 after its Phase 3 LEVEL trial missed its primary endpoint.
● AMIX shares broke out roughly 34% after an investor exercised 857,462 warrants at $5.75 per share, generating roughly $4.9 million in gross proceeds.
● CAPR shares surged 21.91% after the FDA agreed to consider an amendedBiologicslicense application for deramiocel centered on upper-limb skeletal muscle function in Duchenne muscular dystrophy.
● Second-quarter 2026Revenuefell about 76% to roughly $4.05 million from $17.08 million a year earlier, while the net loss widened to about $55.4 million from $34.7 million.
● AVXL shares surged 14.47% after a fiscal third-quarter update reframed the regulatory path for lead candidate blarcamesine and reassured investors about the company's financial staying power.
● EIKN shares rose 12.46% as investors positioned ahead of the ESMO Congress in late October, where seven abstracts covering the company's pipeline have been accepted.
The latest US sector momentum visualization for 25 August 2026 shows three sectors in Leading, five in Improving, two in Weakening and one in Lagging. The chart indicates an active rotation environment, with momentum strengthening across several sectors while some previous leaders are losing …